Sutro Biopharma (STRO) Other financing activities (2017 - 2025)
Sutro Biopharma recorded quarterly Other financing activities of $66000.0 in Q4 2025, up 164.0% quarter-over-quarter from $25000.0 in Q3 2025, and up 175.0% year-over-year from $24000.0 in Q4 2024.
Sutro Biopharma's Other financing activities history runs 9 years deep, the most recent figure standing at $66000.0 for Q4 2025.
- In Q4 2025, Other financing activities rose 175.0% year-over-year to $66000.0; the TTM figure through Dec 2025 stood at $332000.0 (down 34.77% YoY), while the FY2025 annual figure was $332000.0, down 34.77% from the prior year.
- Other financing activities came in at $66000.0 for Q4 2025 at Sutro Biopharma, up from $25000.0 in the prior quarter.
- In the past five years, Other financing activities ranged from a high of $580000.0 in Q3 2021 to a low of -$135.7 million in Q4 2023.
- A 5-year average of -$7.0 million and a median of $61000.0 in 2025 frame the typical range for Other financing activities.
- Across the five-year window, Other financing activities tumbled 91.38% in 2022 and soared 516.67% in 2024, its largest moves.
- Sutro Biopharma's Other financing activities stood at -$84000.0 in 2021, then jumped by 159.52% to $50000.0 in 2022, then tumbled by 271536.0% to -$135.7 million in 2023, then jumped by 100.02% to $24000.0 in 2024, then surged by 175.0% to $66000.0 in 2025.
- According to Business Quant data, Other financing activities over the past three periods registered $66000.0, $25000.0, and $61000.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn |
| 10 | Sutro Biopharma | 242.87 Mn | 242.87 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 66,000.00 |
| Dec 31, 2025 | 66,000.00 |
| Sep 30, 2025 | 25,000.00 |
| Sep 30, 2025 | 25,000.00 |
| Jun 30, 2025 | 61,000.00 |
| Jun 30, 2025 | 61,000.00 |
| Mar 31, 2025 | 180,000.00 |
| Mar 31, 2025 | 180,000.00 |
| Dec 31, 2024 | 24,000.00 |
| Dec 31, 2024 | 24,000.00 |
| Sep 30, 2024 | 74,000.00 |
| Sep 30, 2024 | 74,000.00 |
| Jun 30, 2024 | 37,000.00 |
| Jun 30, 2024 | 37,000.00 |
| Mar 31, 2024 | 374,000.00 |
| Mar 31, 2024 | 374,000.00 |
| Dec 31, 2023 | -135.72 Mn |
| Dec 31, 2023 | -135.72 Mn |
| Sep 30, 2023 | 33,000.00 |
| Sep 30, 2023 | 33,000.00 |
| Jun 30, 2023 | 6,000.00 |
| Jun 30, 2023 | 6,000.00 |
| Mar 31, 2023 | 451,000.00 |
| Mar 31, 2023 | 451,000.00 |
| Sep 30, 2022 | 50,000.00 |
| Sep 30, 2022 | 50,000.00 |
| Jun 30, 2022 | 9,000.00 |
| Jun 30, 2022 | 9,000.00 |
| Mar 31, 2022 | 404,000.00 |
| Mar 31, 2022 | 404,000.00 |
| Dec 31, 2021 | -84,000.00 |
| Dec 31, 2021 | -84,000.00 |
| Sep 30, 2021 | 580,000.00 |
| Sep 30, 2021 | 580,000.00 |
| Jun 30, 2021 | 84,000.00 |
| Jun 30, 2021 | 84,000.00 |
| Mar 31, 2021 | 407,000.00 |
| Mar 31, 2021 | 407,000.00 |
| Dec 31, 2020 | -6.87 Mn |
| Dec 31, 2020 | -6.87 Mn |
| Sep 30, 2020 | 314,000.00 |
| Sep 30, 2020 | 314,000.00 |
| Dec 31, 2019 | 297,000.00 |
| Dec 31, 2019 | 297,000.00 |
| Sep 30, 2019 | 297,000.00 |
| Sep 30, 2019 | 297,000.00 |
| Dec 31, 2018 | -2.41 Mn |
| Dec 31, 2018 | -2.41 Mn |
| Sep 30, 2018 | 1.88 Mn |
| Sep 30, 2018 | 1.88 Mn |
| Jun 30, 2018 | 482,000.00 |
| Jun 30, 2018 | 482,000.00 |
| Mar 31, 2018 | 52,000.00 |
| Mar 31, 2018 | 52,000.00 |
| Dec 31, 2017 | 96,000.00 |
| Dec 31, 2017 | 96,000.00 |